CO5611149A2 - Forma de presentacion para administracion por vial oral, que comprende ester etilico de acido 3-[(2-{[4-(hexiloxicarbonilo amino-imino-metil)-fenilamino]-metil}-1-metil-1h-bencilimi dazol-5-carbonil)-piridin-2-il-amino]-propionico y un nucleo que com - Google Patents

Forma de presentacion para administracion por vial oral, que comprende ester etilico de acido 3-[(2-{[4-(hexiloxicarbonilo amino-imino-metil)-fenilamino]-metil}-1-metil-1h-bencilimi dazol-5-carbonil)-piridin-2-il-amino]-propionico y un nucleo que com

Info

Publication number
CO5611149A2
CO5611149A2 CO04099830A CO04099830A CO5611149A2 CO 5611149 A2 CO5611149 A2 CO 5611149A2 CO 04099830 A CO04099830 A CO 04099830A CO 04099830 A CO04099830 A CO 04099830A CO 5611149 A2 CO5611149 A2 CO 5611149A2
Authority
CO
Colombia
Prior art keywords
acid
methyl
amino
pharmaceutical composition
pharmaceutically acceptable
Prior art date
Application number
CO04099830A
Other languages
English (en)
Inventor
Brauns Ulrich
Norbert Hauel
Original Assignee
Boehringer Ingelheim Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27789735&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CO5611149(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from DE10209985A external-priority patent/DE10209985A1/de
Priority claimed from DE2002145624 external-priority patent/DE10245624A1/de
Application filed by Boehringer Ingelheim Pharma filed Critical Boehringer Ingelheim Pharma
Publication of CO5611149A2 publication Critical patent/CO5611149A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D235/14—Radicals substituted by nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

1.- Composición farmacéutica para administración por vía oral, que comprende al menos a) éster etílico de ácido 3-[(2-{[4-(hexiloxicarbonilamino-imino-metil)-fenilamino]-metil}-1-metil-1H-bencimidazol-5-carbonil)-piridin-2-iI-amino]-propiónico o una de sus sales farmacéuticamente aceptables, y b) uno o varios ácidos orgánicos farmacéuticamente aceptables, con una solubilidad en agua > 1 g / 250 ml a 20°C.2.- Composición farmacéutica según la reivindicación 1, en la cual el ácido orgánico farmacéuticamente aceptable es ácido tartárico, ácido fumárico, ácido succínico, ácido cítrico, ácido málico, ácido glutámico y ácido aspártico, o uno de sus hidratos o sales ácidas.3.- Composición farmacéutica según la reivindicación 2, caracterizada porque el ácido orgánico farmacéuticamente aceptable es ácido tartárico, ácido fumárico, ácido cítrico o ácido succínico.4.- Composición farmacéutica según la reivindicación 3, caracterizada porque el ácido orgánico farmacéuticamente aceptable es ácido tartárico.5.- Composición farmacéutica según una de las reivindicaciones 1 a 4, en la cual el contenido de éster etílico de ácido 3-[(2-{[4-(hexiloxicarbonilamino-imino-metil)-fenilamino]-metil}-1-metil-1H-bencimidazol-5-carbonil)-piridin-2-il-amino]-propiónico o de sus sales en la composición farmacéutica asciende a 5 hasta 60%.6.- Composición farmacéutica según las reivindicaciones 1 a 5, en la cual el contenido de ácido orgánico farmacéuticamente aceptable asciende a 20 hasta 90%.7.- Composición farmacéutica según la reivindicación 1 a 6, que comprende un material de núcleo aproximadamente esférico, que está compuesto por el ácido orgánico farmacéuticamente aceptable, o lo contiene, y una capa de sustancia activa que contiene agente aglutinante y eventualmente agente disgregante, que circunda al material de núcleo.
CO04099830A 2002-03-07 2004-10-06 Forma de presentacion para administracion por vial oral, que comprende ester etilico de acido 3-[(2-{[4-(hexiloxicarbonilo amino-imino-metil)-fenilamino]-metil}-1-metil-1h-bencilimi dazol-5-carbonil)-piridin-2-il-amino]-propionico y un nucleo que com CO5611149A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10209985A DE10209985A1 (de) 2002-03-07 2002-03-07 Oral zu applizierende Darreichungsform für 3-[(2-{[4-(Hexyloxycarbonylaminoimino-methyl)-phenylamino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propinsäure-ethylester und dessen Salze
DE2002145624 DE10245624A1 (de) 2002-09-30 2002-09-30 Oral zu applizierende Darreichungsform für 3-[(2-{[4-(Hexyloxycarbonylaminoimino-methyl)-phenylamino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2yl-amino]-propinsäure-ethylester und dessen Salze

Publications (1)

Publication Number Publication Date
CO5611149A2 true CO5611149A2 (es) 2006-02-28

Family

ID=27789735

Family Applications (1)

Application Number Title Priority Date Filing Date
CO04099830A CO5611149A2 (es) 2002-03-07 2004-10-06 Forma de presentacion para administracion por vial oral, que comprende ester etilico de acido 3-[(2-{[4-(hexiloxicarbonilo amino-imino-metil)-fenilamino]-metil}-1-metil-1h-bencilimi dazol-5-carbonil)-piridin-2-il-amino]-propionico y un nucleo que com

Country Status (36)

Country Link
US (2) US20190231766A1 (es)
EP (2) EP1485094B2 (es)
JP (3) JP3866715B2 (es)
KR (1) KR101005716B1 (es)
CN (1) CN100528157C (es)
AR (2) AR042861A1 (es)
AT (1) ATE540943T1 (es)
AU (1) AU2003210400B8 (es)
BR (1) BRPI0306559B8 (es)
CA (1) CA2476054C (es)
CL (1) CL2009001915A1 (es)
CO (1) CO5611149A2 (es)
CY (4) CY1112796T1 (es)
DE (1) DE122012000047I1 (es)
DK (2) DK1870100T3 (es)
EA (1) EA009664B1 (es)
EC (1) ECSP045331A (es)
ES (2) ES2390661T5 (es)
HK (1) HK1078792A1 (es)
HR (1) HRP20040807B1 (es)
IL (3) IL163863A0 (es)
LU (2) LU92025I2 (es)
ME (1) ME00325B (es)
MX (1) MXPA04008542A (es)
MY (1) MY143734A (es)
NO (3) NO326918B1 (es)
NZ (2) NZ535663A (es)
PE (1) PE20030889A1 (es)
PL (2) PL212566B1 (es)
PT (2) PT1870100E (es)
RS (1) RS52088B (es)
SG (1) SG146435A1 (es)
SI (2) SI1870100T1 (es)
TW (1) TWI293879B (es)
WO (1) WO2003074056A1 (es)
ZA (1) ZA200406071B (es)

Families Citing this family (86)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030181488A1 (en) 2002-03-07 2003-09-25 Boehringer Ingelheim Pharma Gmbh & Co. Kg Administration form for the oral application of 3-[(2-{[4-(hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionic acid ethyl ester and the salts thereof
US20050070537A1 (en) 2002-10-10 2005-03-31 Chris Rundfeldt Use of dihydroimidazolones for the treatment of dogs
DE10337697A1 (de) * 2003-08-16 2005-03-24 Boehringer Ingelheim Pharma Gmbh & Co. Kg Tablette enthaltend 3-[(2-{[4-(Hexyloxycarbonylamino-imino-methyl)-phenyl-amino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionsäure-ethylester oder dessen Salze
DE10339862A1 (de) * 2003-08-29 2005-03-24 Boehringer Ingelheim Pharma Gmbh & Co. Kg 3-[(2-{[4-(Hexyloxycarbonylamino-imino-methyl)- phenylamino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionsäure-ethylester-Methansulfonat und dessen Verwendung als Arzneimittel
DE10341043A1 (de) * 2003-09-03 2005-03-31 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue oral zu applizierende Darreichungsform für 3-[(2-{[4-Hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionsäure-ethylester und dessen Salze
JPWO2005113010A1 (ja) * 2004-05-24 2008-07-31 クオリカプス株式会社 表面改質および溶解性が改善された硬カプセル
DE102004062864A1 (de) 2004-12-21 2006-06-22 Boehringer Ingelheim Pharma Gmbh & Co. Kg Folienbehälter
US20060222640A1 (en) * 2005-03-29 2006-10-05 Boehringer Ingelheim International Gmbh New pharmaceutical compositions for treatment of thrombosis
DE102005025728A1 (de) 2005-06-04 2006-12-07 Boehringer Ingelheim Pharma Gmbh & Co. Kg Polymorphe von 3-[(2-{[4-(Hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-Propionsäure-ethylester
DE102005061623A1 (de) * 2005-12-21 2007-06-28 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verbessertes Verfahren zur Herstellung von 4-(Benzimidazolylmethylamino)-Benzamidinen und deren Salzen
DE102005061624A1 (de) * 2005-12-21 2007-06-28 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verbessertes Verfahren zur Herstellung von Salzen von 4-(Benzimidazolylmethylamino)-Benzamidinen
BRPI0715492A2 (pt) * 2006-07-17 2013-03-19 Boehringer Ingelheim Int uso de inibidores diretos de trombina
WO2008009640A1 (en) * 2006-07-17 2008-01-24 Boehringer Ingelheim International Gmbh New paediatric indications for direct thrombin inhibitors
US20100087488A1 (en) * 2006-10-10 2010-04-08 Boehringer Ingelheim International Gmgh Physiologically Acceptable Salts of 3-[(2--1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionic acid ethyl ester
CN101980697A (zh) * 2008-03-28 2011-02-23 贝林格尔.英格海姆国际有限公司 制备口服给药的达比加群制剂的方法
EP2271317B1 (de) 2008-03-28 2017-04-19 Boehringer Ingelheim International GmbH Verfahren zur herstellung von säurepellets
NZ589746A (en) * 2008-07-14 2012-10-26 Boehringer Ingelheim Int Method for manufacturing medicinal compounds containing dabigatran
US9186411B2 (en) 2008-07-28 2015-11-17 Takeda Pharmaceutical Company Limited Pharmaceutical composition
CA2734804A1 (en) * 2008-08-19 2010-02-25 Boehringer Ingelheim International Gmbh Use of dabigatranetexilate for treating patients with pulmonary hypertension
EA201100358A1 (ru) * 2008-08-19 2011-10-31 Бёрингер Ингельхайм Интернациональ Гмбх Дабигатран для чрескожной хирургической катетеризации сердца
EP2647375A1 (en) 2009-05-14 2013-10-09 Boehringer Ingelheim International Gmbh Combination of vargatef and dabigatran for the treatment of oncological and fibrotic diseases
TW201124143A (en) 2009-08-24 2011-07-16 Boehringer Ingelheim Int Emergency interventions of active charcoal with dabigatran etexilate overdosing
US20130052262A1 (en) * 2010-03-01 2013-02-28 Sandra Brueck Dabigatran etexilate-containing oral pharmaceutical composition
US20130149346A1 (en) 2010-03-08 2013-06-13 ratiopharm GmbH Graf-Arco-Strasse 3 Dabigatran etexilate-containing pharmaceutical composition
EP2588090B2 (en) 2010-07-01 2023-11-22 KRKA, tovarna zdravil, d.d., Novo mesto Pharmaceutical oral dosage forms comprising dabigatran etexilate and its pharmaceutically acceptable salts
CN103025715A (zh) 2010-07-09 2013-04-03 埃斯特维化学股份有限公司 用于制备凝血酶特异性抑制剂的中间体和方法
EP2937343A1 (en) 2010-07-09 2015-10-28 Esteve Química, S.A. Process of preparing a thrombin specific inhibitor
WO2012044595A1 (en) 2010-09-27 2012-04-05 Ratiopharm Gmbh Dabigatran etexilate bismesylate salt, solid state forms and process for preparation thereof
EA201391758A1 (ru) * 2011-05-24 2014-06-30 Тева Фармасьютикал Индастриз Лтд. Спрессованная сердцевина для фармацевтической композиции, содержащая органические кислоты
CN102391250B (zh) * 2011-08-29 2013-06-19 石药集团欧意药业有限公司 一种达比加群酯化合物、制备方法及其药物组合物
CN103998024A (zh) * 2011-12-22 2014-08-20 勃林格殷格翰国际有限公司 速释多单元微丸系统
US9212166B2 (en) 2012-01-20 2015-12-15 Cadila Healthcare Limited Process for the preparation of dabigatran etexilate mesylate and polymorphs of intermediates thereof
JP2015504903A (ja) 2012-01-24 2015-02-16 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 新規の経口投与用ダビガトラン製剤
EP2817000B1 (en) * 2012-02-21 2021-08-04 Towa Pharmaceutical Europe, S.L. Oral pharmaceutical compositions of dabigatran etexilate
EP2631234A1 (en) 2012-02-23 2013-08-28 Esteve Química, S.A. Solid forms of dabigatran etexilate mesylate and processes for their preparation
WO2013144971A1 (en) 2012-03-27 2013-10-03 Cadila Healthcare Limited New solid forms of dabigatran etexilate bisulfate and mesylate and processes to prepare them
WO2013150545A2 (en) 2012-04-02 2013-10-10 Msn Laboratories Limited Process for the preparation of benzimidazole derivatives and salts thereof
US20130345262A1 (en) 2012-06-25 2013-12-26 Boehringer Ingelheim International Gmbh Method for prevention of stroke
IN2015DN02616A (es) 2012-09-28 2015-09-18 Ranbaxy Lab Ltd
EP2900652A2 (en) 2012-09-28 2015-08-05 Ranbaxy Laboratories Limited Process for the preparation of dabigatran etexilate or pharmaceutically acceptable salt thereof
EP2722033A1 (en) 2012-10-19 2014-04-23 Sanovel Ilac Sanayi ve Ticaret A.S. Pharmaceutical Compositions of Dabigatran Free Base
WO2014060561A1 (en) 2012-10-19 2014-04-24 Sanovel Ilac Sanayi Ve Ticaret A.S. Oral pharmaceutical formulations comprising dabigatran
EP2740471B1 (en) 2012-12-07 2015-05-27 Hexal AG Oral pharmaceutical composition comprising dabigatran etexilate
CN103127109B (zh) * 2013-02-05 2014-08-13 南京华威医药科技开发有限公司 含达比加群酯或其盐和水合物的药用组合
EP2835370A1 (en) 2013-08-08 2015-02-11 Medichem, S.A. New crystals of dabigatran etexilate mesylate
CN104414995A (zh) * 2013-09-04 2015-03-18 天津汉瑞药业有限公司 甲磺酸达比加群酯的药用组合物
EP2853260A1 (en) 2013-09-27 2015-04-01 ratiopharm GmbH Pharmaceutical preparation comprising dabigatran etexilate bismesylate
US9820988B2 (en) 2014-03-24 2017-11-21 Boehringer Ingelheim Vetmedica Gmbh Treatment of epileptic disorders in feline animals
IN2014MU01042A (es) 2014-03-26 2015-10-02 Cadila Healthcare Ltd
EP2929884A1 (en) 2014-04-11 2015-10-14 Sanovel Ilac Sanayi ve Ticaret A.S. Pharmaceutical combinations of dabigatran and h2-receptor antagonists
WO2015155281A1 (en) 2014-04-11 2015-10-15 Sanovel Ilac Sanayi Ve Ticaret A.S. Pharmaceutical combinations of dabigatran and proton pump inhibitors
DE102014108210A1 (de) 2014-06-11 2015-12-17 Dietrich Gulba Rodentizid
CA3001495C (en) * 2014-11-03 2021-07-20 Solipharma Llc Formulations of dabigatran etexilate or dabigatran etexilate salts and preparation methods thereof
CN105640909B (zh) * 2014-11-14 2019-09-20 正大天晴药业集团股份有限公司 一种含有达比加群酯的药用组合物
CN106924256B (zh) * 2015-12-25 2022-08-19 深圳市药欣生物科技有限公司 药物组合物及其制备方法
CN105797162B (zh) * 2014-12-31 2022-10-25 昆明积大制药股份有限公司 药用辅料表面改性方法
WO2016107605A1 (zh) 2014-12-31 2016-07-07 昆明积大制药股份有限公司 药物组合物及其制备方法
TR201502223A2 (tr) 2015-02-25 2016-09-21 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Dronedaron ve dabigatranın farmasötik kombinasyonları.
WO2016161576A1 (zh) * 2015-04-08 2016-10-13 杭州领业医药科技有限公司 一种含半胱氨酸盐酸盐的微丸及其制备方法
MA42480A (fr) 2015-07-20 2018-05-30 Sanovel Ilac Sanayi Ve Ticaret As Préparations pharmaceutiques de dabigatran sous forme de base libre
CN105919962B (zh) * 2015-12-18 2019-01-18 重庆两江药物研发中心有限公司 一种达比加群酯片剂及其制备方法
EP3184102A1 (en) 2015-12-23 2017-06-28 Hexal AG Pharmaceutical composition of vortioxetine hydrobromide comprising an inert core formed of an acidic reacting compound
WO2017111637A1 (en) 2015-12-23 2017-06-29 Zaklady Farmaceutyczne Polpharma Sa Pharmaceutical composition comprising dabigatran or a pharmaceutically acceptable salt thereof
US10449195B2 (en) 2016-03-29 2019-10-22 Shenzhen Pharmacin Co., Ltd. Pharmaceutical formulation of palbociclib and a preparation method thereof
TR201606697A2 (tr) 2016-05-20 2017-12-21 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Dabi̇gatranin yeni̇ oral farmasöti̇k formülasyonlari
WO2018104387A1 (en) 2016-12-07 2018-06-14 Sanovel Ilac Sanayi Ve Ticaret A.S. Multilayered tablet compositions of dabigatran
TR201617984A2 (tr) 2016-12-07 2018-06-21 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Dabi̇gatranin farmasöti̇k kompozi̇syonlari
EP3342401A1 (en) 2016-12-28 2018-07-04 Sanovel Ilac Sanayi ve Ticaret A.S. Bilayer tablet formulations of dabigatran etexilate
JP2018184375A (ja) 2017-04-27 2018-11-22 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ダビガトランエテキシラート又は医薬的に許容されるその塩を含む錠剤及びその製造方法
WO2018229784A1 (en) * 2017-06-14 2018-12-20 Natco Pharma Limited Pharmaceutical compositions of dabigatran
CN109125274A (zh) * 2017-06-28 2019-01-04 上海美悦生物科技发展有限公司 注射用苯并咪唑类药用酸组合物及其制备方法和用途
TR201722323A2 (tr) 2017-12-27 2019-07-22 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Dabi̇gatranin oral farmasöti̇k kompozi̇syonlari
TR201722186A2 (tr) 2017-12-27 2019-07-22 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Dabi̇gatranin farmasöti̇k kompozi̇syonlari
TR201722353A2 (tr) 2017-12-27 2019-07-22 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Dabi̇gatran eteksi̇lat i̇çeren oral uygulama i̇çi̇n farmasöti̇k formülasyon
TR201722630A2 (es) 2017-12-28 2019-07-22 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi
CN110339193B (zh) 2018-04-04 2022-04-29 上海汉都医药科技有限公司 含达比加群酯的药物组合物及其制备方法
KR20200082641A (ko) 2018-12-31 2020-07-08 주식회사 유영제약 다비가트란 에텍실레이트를 포함하는 약제학적 조성물
EP3771465A1 (en) 2019-08-01 2021-02-03 Zaklady Farmaceutyczne Polpharma SA Pharmaceutical composition comprising dabigatran etexilate
KR20210157691A (ko) 2020-06-22 2021-12-29 한국유나이티드제약 주식회사 다비가트란 에텍실레이트를 포함하는 경구용 약학조성물
KR20210157693A (ko) 2020-06-22 2021-12-29 한국유나이티드제약 주식회사 다비가트란 에텍실레이트를 포함하는 경구용 약학조성물
KR20210157692A (ko) 2020-06-22 2021-12-29 한국유나이티드제약 주식회사 다비가트란 에텍실레이트를 포함하는 경구용 약학조성물
CN114306245A (zh) 2020-09-29 2022-04-12 深圳市药欣生物科技有限公司 无定形固体分散体的药物组合物及其制备方法
EP4070658A1 (de) 2021-04-06 2022-10-12 BIORoxx GmbH Verwendung von blutgerinnungshemmenden verbindungen als rodentizide
CN115227663B (zh) * 2021-04-22 2023-12-12 石药集团恩必普药业有限公司 一种甲磺酸达比加群酯胶囊及其制备方法
WO2023139243A1 (en) 2022-01-21 2023-07-27 Adamed Pharma S.A A process for preparation of tartaric acid cores for dabigatran pellets and the pellets containing dabigatran
GR1010399B (el) * 2022-04-05 2023-02-03 Φαρματεν Α.Β.Ε.Ε., Φαρμακευτικο σκευασμα που περιλαμβανει εναν αντιπηκτικο παραγοντα και μεθοδος παραγωγης αυτου

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6087380A (en) * 1949-11-24 2000-07-11 Boehringer Ingelheim Pharma Kg Disubstituted bicyclic heterocycles, the preparations and the use thereof as pharmaceutical compositions
DE3126703A1 (de) * 1981-07-07 1983-01-27 Dr. Karl Thomae Gmbh, 7950 Biberach Bromhexin-retardform und verfahren zu ihrer herstellung
JPS58134033A (ja) * 1982-02-02 1983-08-10 Fujisawa Pharmaceut Co Ltd 医薬組成物
PE121699A1 (es) * 1997-02-18 1999-12-08 Boehringer Ingelheim Pharma Heterociclos biciclicos disustituidos como inhibidores de la trombina
DE10133786A1 (de) * 2001-07-16 2003-02-06 Boehringer Ingelheim Pharma Verwendung von Thrombin-Inhibitoren zur Behandlung von Arthritis

Also Published As

Publication number Publication date
ES2390661T3 (es) 2012-11-15
EP1485094B2 (de) 2020-03-25
BRPI0306559B8 (pt) 2021-05-25
ECSP045331A (es) 2006-04-19
CY2012031I2 (el) 2015-08-05
ES2380704T3 (es) 2012-05-17
DE122012000047I1 (de) 2012-09-13
WO2003074056A1 (de) 2003-09-12
JP3866715B2 (ja) 2007-01-10
MXPA04008542A (es) 2004-12-06
MEP50708A (en) 2011-02-10
SI1485094T2 (sl) 2020-08-31
NO332209B1 (no) 2012-07-30
NO326918B1 (no) 2009-03-16
PL212566B1 (pl) 2012-10-31
IL163863A0 (en) 2005-12-18
CY2012020I1 (el) 2015-08-05
AU2003210400B2 (en) 2008-08-07
NO2013001I2 (no) 2014-09-01
ES2390661T5 (es) 2020-12-04
JP2006328081A (ja) 2006-12-07
DK1485094T4 (da) 2020-06-22
JP2007056018A (ja) 2007-03-08
CY1113158T1 (el) 2015-08-05
AU2003210400A1 (en) 2003-09-16
CY1112796T1 (el) 2015-08-05
DK1485094T3 (da) 2012-10-15
ATE540943T1 (de) 2012-01-15
BRPI0306559B1 (pt) 2021-05-18
NO20042361L (no) 2004-06-07
AR072385A2 (es) 2010-08-25
IL163863A (en) 2013-02-28
BR0306559A (pt) 2004-11-30
NZ535663A (en) 2006-06-30
EP1485094A1 (de) 2004-12-15
EP1870100A1 (de) 2007-12-26
EA200401136A1 (ru) 2005-04-28
DK1870100T3 (da) 2012-05-14
PT1485094E (pt) 2012-10-09
ZA200406071B (en) 2005-11-30
AR042861A1 (es) 2005-07-06
CN100528157C (zh) 2009-08-19
NO20042361D0 (no) 2004-06-07
CN1638771A (zh) 2005-07-13
LU92117I2 (fr) 2013-02-19
TWI293879B (en) 2008-03-01
CY2012031I1 (el) 2015-08-05
SI1870100T1 (sl) 2012-05-31
ES2380704T9 (es) 2013-07-24
KR101005716B1 (ko) 2011-01-05
US20190231766A1 (en) 2019-08-01
HRP20040807A2 (en) 2005-02-28
EA009664B1 (ru) 2008-02-28
IL209368A (en) 2012-10-31
LU92025I2 (fr) 2012-08-20
JP4953727B2 (ja) 2012-06-13
EP1870100B1 (de) 2012-01-11
EP1485094B1 (de) 2012-07-04
HK1078792A1 (en) 2006-03-24
RS52088B (sr) 2012-06-30
NO2013001I1 (no) 2013-02-11
RS79204A (en) 2007-02-05
TW200306188A (en) 2003-11-16
CA2476054C (en) 2011-11-08
ME00325B (me) 2011-05-10
SI1485094T1 (sl) 2012-10-30
CL2009001915A1 (es) 2010-02-12
AU2003210400B8 (en) 2008-09-25
PL370517A1 (en) 2005-05-30
JP2005519099A (ja) 2005-06-30
PL394601A1 (pl) 2011-07-18
PT1870100E (pt) 2012-04-17
CY2012020I2 (el) 2015-08-05
MY143734A (en) 2011-07-15
US20200085807A1 (en) 2020-03-19
KR20040099298A (ko) 2004-11-26
PL210862B1 (pl) 2012-03-30
PE20030889A1 (es) 2003-12-10
IL209368A0 (en) 2011-01-31
CA2476054A1 (en) 2003-09-12
NZ546367A (en) 2008-08-29
NO20081304L (no) 2004-06-07
HRP20040807B1 (hr) 2014-11-21
SG146435A1 (en) 2008-10-30

Similar Documents

Publication Publication Date Title
CO5611149A2 (es) Forma de presentacion para administracion por vial oral, que comprende ester etilico de acido 3-[(2-{[4-(hexiloxicarbonilo amino-imino-metil)-fenilamino]-metil}-1-metil-1h-bencilimi dazol-5-carbonil)-piridin-2-il-amino]-propionico y un nucleo que com
ATE464062T1 (de) Stabilisierte flüssige pharmazeutische zusammensetzung enthaltend tfpi
ES2307041T3 (es) Tableta que contiene ester etilico del acido 3-((2-((4-(hexiloxicarbonilamino-imino-metil)-fenilamino)-metil)-1-metil-1h-bencimidazol-5-carbonil)-piridin-2-il-amino)-propionico o sus sales.
ES2546847T3 (es) Formulaciones de un inhibidor de la Src/Abl
ES2330023T3 (es) Derivados de aril-o-piperidina para el tratamiento de problemas relacionados con la diabetes.
ES2101164T3 (es) Composiciones farmaceuticas orales para el suministro especifico al colon.
UY27320A1 (es) Nuevas composiciones farmacéuticas
PE20060298A1 (es) Derivados de acido carboxilico de bencimidazolona
JP2005508981A5 (es)
ECSP055910A (es) Nuevos acidos carboxilicos y sus esteres, medicamentos que contienen estos compuestos y procedimientos para su preparacion
PE20061439A1 (es) DERIVADOS DE 2-AMIDO-6-AMINO-8-OXO-PURINA COMO MODULADORES DEL RECEPTOR Toll (TLR)
PE20030128A1 (es) Formulaciones autoemulsionantes de inhibidores de la proteina de transferencia de colesteril ester
ES2184310T3 (es) Formulacion autoemulsionante para compuestos lipofilos acidos.
ATE482700T1 (de) Stabilisierte pharmazeutische zusammensetzung
ITMI20061672A1 (it) Formulazioni di acido acetilsalicilico o suoi derivati in capsule molli,esibenti elevata stabilita'
BRPI0507848A (pt) composição farmacêutica para aplicação oral e método para prepará-la
PE20080766A1 (es) Sales de benzimidazolil piridil eteres y formulaciones que las contienen
DE60042831D1 (de) Pharmazeutisch aktive sulfonylaminosäurederivate
Zhu et al. The discovery of azetidine-piperazine di-amides as potent, selective and reversible monoacylglycerol lipase (MAGL) inhibitors
GT199800196A (es) Combinaciones de estatina-eter carboxialquilico.
GT200300017A (es) Sistema de suministro osmotico
ES2211954T3 (es) Composicion farmaceutica oral de compuestos de piperidinoalcanol en forma de solucion.
PE20030092A1 (es) Formulacion de una solucion de inhalacion con una sal de tiotropio
UA95601C2 (ru) Метансульфонат этилового эфира 3-[(2-{[4-(гексилоксикарбониламиноиминометил)фениламино]метил}-1метил-1н- бензимидазол-5-карбонил)пиридин-2-иламино]пропионовой кислоты и фармацевтическая композиция, которая его содержит
PE20020055A1 (es) Formulaciones estables liquidas y solidas que comprenden una antihistamina no sedante y un descongestionante nasal

Legal Events

Date Code Title Description
FG Application granted